Will widespread human papillomavirus prophylactic vaccination change sexual practices of adolescent and young adult women in America?

Obstetrics and Gynecology

Volumn 108, Issue 2, 2006, Pages 420-424

  Monk, Bradley J ^a   Wiley, Dorothy J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

MERCURY DERIVATIVE; THIOMERSAL; WART VIRUS VACCINE;

ANTIBODY PRODUCTION; AUTISM; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CLINICAL TRIAL; CONTRACEPTION; COST EFFECTIVENESS ANALYSIS; DEVELOPMENTAL DISORDER; DRUG EFFICACY; DRUG SAFETY; FEMALE; HIGH RISK BEHAVIOR; HUMAN; INFECTION CONTROL; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; NEUROLOGIC DISEASE; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; SEXUAL BEHAVIOR; SEXUAL EDUCATION; SINGLE DRUG DOSE; UNITED STATES; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VIRION; VIRUS INFECTION; VIRUS PARTICLE; WART VIRUS;

ADOLESCENT; ADOLESCENT BEHAVIOR; ADOLESCENT HEALTH SERVICES; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SEXUAL BEHAVIOR; UNITED STATES; UTERINE CERVICAL NEOPLASMS; VACCINATION; VIRAL VACCINES;

EID: 33748093383     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.AOG.0000228509.11502.d2     Document Type: Review

References (31)

1. Mahdavi A, Monk BJ. Vaccines against human papillomavirus and cervical cancer: promises and challenges. Oncologist 2005;10:528-38.
2. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347:1645-51.
3. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-8.
4. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004;364:1757-65.
5. Verstraeten T, Davis RL, DeStefano F, Lieu TA, Rhodes PH, Black SB, et al. Safety of thimerosal-containing vaccines: a two-phased study of computerized health maintenance organization databases. Pediatrics 2003;112:1039-48.
6. Heron J, Golding J, ALSPCA Study Team. Thimerosal exposure in infants and developmental disorders: a prospective cohort study in the United kingdom does not support a causal association. Pediatrics 2004;114:577-83.
7. Davidson PW, Palumbo D, Myers GJ, Cox C, Shamlaye CF, Sloane-Reeves J, et al. Neurodevelopmental outcomes of Seychellois children from the pilot cohort at 108 months following prenatal exposure to methylmercury from a maternal fish diet. Environ Res 2000;84:1-11.
8. Myers GJ, Davidson PW, Cox C, Shamlaye CF, Tanner MA, Marsh DO, et al. Summary of the Seychelles child development study on the relationship of fetal methylmercury exposure to neurodevelopment. Neurotoxicology 1995;16:711-6.
9. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski, B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367:1247-55.
10. Merck's Investigational Vaccine GARDASIL™ Prevented 100 Percent of Cervical Pre-cancers and Non-invasive Cervical Cancers Associated with HPV Types 16 and 18 in New Clinical Study. Available at: http://www.merck.com/newsroom/ press_releases/research_and_development/2005_1006.html. Retrieved May 16, 2006.
11. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88:63-73.
12. Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention. Available at: http://www.cdc.gov/nip/ACIP/. Retrieved May 16, 2006.
13. Vaccines and Sex, editorial, Chicago Tribune, November 4, 2005. Available at http://www.highbeam.com/library/doc0.asp?DOCID=1G1:138327657&hum= 2&ctrlInfo=Round20%3AMode20e%3ASR%3AResult&ao=&FreePremium=BOTH. Retrieved May 17, 2006.
14. Trends in sexual risk behaviors among high school students-United States, 1991-2001. MMWR Morb Mortal Wkly Rep 2002;51:856-9.
15. Friedman HL. Changing patterns of adolescent sexual behavior: consequences for health and development. J Adolesc Health 1992;13:345-50
16. Kirby D, Brener ND, Brown NL, Peterfreund N, Hillard P, Harrist R. The impact of condom availability [correction of distribution] in Seattle schools on sexual behavior and condom use. Am J Public Health 1999;89:182-7.
17. Abma JC, Martinez GM, Mosher WD, Dawson BS. Teenagers in the United States: sexual activity, contraceptive use, and childbearing, 2002. Vital Health Stat 2004;24:1-48.
18. Kirkkola AL, Mattila K, Virjo I. Problems with condoms - a population-based study among Finnish men and women. Eur J Contracept Reprod Health Care. 2005;10:87-92.
19. Harper CC, Cheong M, Rocca CH, Darney PD, Raine TR. The effect of increased access to emergency contraception among young adolescents. Obstet Gynecol 2005;106:483-91.
20. DiIorio C, Kelley M. Hockenberry-Eaton M. Communication about sexual issues: mothers, fathers, and friends. J Adolesc Health 1999;24:181-9.
21. Kaestle CE, Morisky DE, Wiley DJ. Sexual intercourse and the age difference between adolescent females and their romantic partners. Perspect Sex Reprod Health 2002;34:304-9.
22. DiClemente RJ, Wingood GM, Crosby R, Sionean C, Cobb BK, Harrington K, et al. Parental monitoring: association with adolescents' risk behaviors. Pediatrics 2001;107:1363-8.
23. Tayler LD. Effects of visual and verbal sexual television content and perceived realism on attitudes and beliefs. J Sex Res 2005;42:130-7.
24. Brown JD, L'Engle KL, Pardun CJ, Guo G, Kenneavy K, Jackson C. Sexy media matter: exposure to sexual content in music, movies, television, and magazines predicts black and white adolescents' sexual behavior. Pediatrics 2006;117:1018-27.
25. Ancheta R, Hynes C, Shrier LA. Reproductive health education and sexual risk among high-risk female adolescents and young adults. J Pediatr Adolesc Gynecol 2005;18:105-11.
26. Goldie SJ, Kohli M, Grima D, Weinstein MC, Wright TC, Bosch FX, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004;96:604-15.
27. Elbasha E, Dasbach E, Insinga R. Projecting the Health and Economic Impact of a Quadrivalent HPV Vaccine using a Multi-type Transmission Dynamic Model. 40th National Immunization Conference, Atlanta GA, March 6-9, 2006 Available at: http://cdc.confex.com/cdc/nic2006/techprogram/P10176.HTM.
28. Chang MH, Chen TH, Hsu HM, Wu TC, Kong MS, Liang DC, et al. Prevention of hepatocellular carcinoma by universal vaccination against hepatitis B virus: the effect and problems. Clin Cancer Res 2005;11:7953-7.
29. Edmunds WJ, van de Heijden OG, Eerola M, Gay NJ. Modelling rubella in Europe. Epidemiol Infect 2000;125:617-34.
30. Garnett GP. Role of herd immunity in determining the effect of vaccines against sexually transmitted disease. J Infect Dis 2005;191:S97-S106.
31. Human Papillomavirus Vaccine A Position Statement of the Christian Medical Association. Available at: http://www.cmdahome.org/index.cgi?cat=100117 &art=3168&BISKIT=4231183168&CONT.